Show simple item record

AuthorAl Zein, Mohammad
AuthorBoukhdoud, Mona
AuthorShammaa, Hadi
AuthorMouslem, Hadi
AuthorEl Ayoubi, Lemir Majed
AuthorIratni, Rabah
AuthorIssa, Khodr
AuthorKhachab, Maha
AuthorAssi, Hazem I.
AuthorSahebkar, Amirhossein
AuthorEid, Ali H.
Available date2023-11-05T06:14:28Z
Publication Date2023
Publication NameDrug Discovery Today
ResourceScopus
ISSN13596446
URIhttp://dx.doi.org/10.1016/j.drudis.2023.103669
URIhttp://hdl.handle.net/10576/48997
AbstractThe tremendous success of immunotherapy in clinical trials has led to its establishment as a new pillar of cancer therapy. However, little clinical efficacy has been achieved in microsatellite stable colorectal cancer (MSS-CRC), which constitutes most CRC tumors. Here, we discuss the molecular and genetic heterogeneity of CRC. We review the immune escape mechanisms, and focus on the latest advances in immunotherapy as a treatment modality for CRC. By providing a better understanding of the tumor microenvironment (TME) and the molecular mechanisms underlying immunoevasion, this review offers an insight into developing therapeutic strategies that are effective for patients with various subsets of CRC.
Languageen
PublisherElsevier
Subjectadoptive cell therapy
cancer vaccines
colorectal cancer
CTLA-4
immune checkpoint inhibitor
PD-1
TitleImmunotherapy and immunoevasion of colorectal cancer
TypeArticle Review
Issue Number9
Volume Number28
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record